06.11.2007 13:00:00
|
NanoImaging Services Opens New Operation to Provide Structural Characterization and Validation of Biopharmaceuticals
NanoImaging Services, Inc. has commenced operation of a new business
providing high-resolution, three-dimensional transmission electron
microscope (TEM) imaging services to manufacturers of large molecule
biopharmaceuticals. The service provides fast, accurate structural
characterization and validation of new drug compounds, targets and
assays; promising improved speed and reduced risk at all phases of the
drug development process, from discovery and characterization through
approval and manufacturing.
NanoImaging Services was founded by researchers from The Scripps
Research Institute with financial support from FEI Company
(Nasdaq:FEIC), a leading manufacturer of TEMs and other tools for
nanotechnology. The start-up has also benefited significantly from early
contracts with Merck & Co., one of the world's largest pharmaceutical
manufacturers, including a project to characterize virus-like particles
of human papilloma virus in support of the development of Merck's
recently-introduced Gardasil® vaccine.
"A picture is worth a thousand words; a
three-dimensional model is priceless,” said
Clint Potter, NanoImaging’s president and CEO. "The
ability to directly visualize biomolecular structures helps scientists
and researchers make better choices, earlier and more often, and gives
regulators increased confidence in their interpretation of complex
analytical and clinical data.”
Potter adds, "We can see important
applications for this technology at almost every point in the
development pipeline. In the end, it will help pharmaceutical
manufacturers bring new, safer, more effective products to market
faster, with lower, more predictable development costs.” "Although this technology is well-proven in
the laboratory, we are the first to offer it as a commercial service,
with tightly-controlled processes designed to deliver timely,
high-quality results,” added Bridget
Carragher, NanoImaging’s COO. "We
come from the academic world, where we have worked extensively with
commercial entities, and we understand the frustration clients can feel
over the vagaries of research agreements, changing personnel,
loosely-controlled protocols and intellectual property issues. We
started NanoImaging Services to address those concerns by providing
world-class technical expertise through a professional,
business-oriented service operation.” "Ultimately all pharmaceuticals interact with
living systems at the molecular level,” said
Matthew Harris, vice president and general manager for FEI’s
NanoBiology division. "Three-dimensional
visualization of these structures will certainly play an increasingly
important role in all phases of drug discovery, development and
manufacturing. We are thrilled to be able to support NanoImaging
Services in its efforts to make the practical benefits of this
technology available to the pharmaceutical industry.”
NanoImaging offers a variety of services, from visual inspection and
statistical characterization to sophisticated 3D reconstruction and
antibody/labeling experiments, using TEM procedures that range from
conventional negative staining to advanced cryo techniques with
automated image acquisition and analysis. In the most advanced
applications, samples in physiologic solution are instantly frozen in
vitreous ice to preserve delicate biological structures in their native
hydrated state. Thousands of images, automatically acquired with low
dose techniques, are sorted and averaged together to create
high-contrast, high-resolution (approaching 1nm), low-noise images, and
statistically valid sampling devoid of operator bias. A secure web-based
interface allows clients to view images and direct experiments remotely,
in real time. Results, along with all meta data, are stored in a
relational database, preserving the provenance of all images for
documentary purposes and providing a basis for long-term studies.
Potter and Carragher, NanoImaging’s founders,
both hold faculty appointments at The Scripps Research Institute in La
Jolla, California, where they jointly manage the Automated Molecular
Imaging research group. They have published extensively on TEM
technology and the science it enables.
NanoImaging Services, Inc. is located at 4045 Sorrento Valley Blvd., San
Diego, CA 92121, USA. For more information, please visit www.nanoimagingservices.com.
Editor Background NanoImaging Services, Inc. provides transmission electron
microscope imaging services to the pharmaceutical, biotechnology and
nanotechnology industries, and specializes in the characterization of
large biological molecules used in biopharmaceuticals such as vaccines,
antibodies, cytokines, hormones and gene therapies. In contrast to
conventional (small molecule) drugs, biopharmaceuticals are typically
protein-based and manufactured in controlled, modified, biological
systems. Their complexity and similarity to naturally occurring
compounds makes a detailed understanding of their structure, and its
relationship to their safety and efficacy, essential in their
development and approval. Biopharmaceuticals represent an important and
rapidly-growing segment of the pharmaceutical industry. For more
information, visit www.nanoimagingservices.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.